Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Summary

The purpose of this study is to look at the effectiveness of giving patients who have been newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared to the widely employed "watch and wait" (best supportive care) approach for early stage PMF, in which patients are followed closely and treatment initiated only if the disease progresses.

Timeline

Start

2013-01

Primary completion

2017-06

Completion

2017-06

Drugs

Indications